• Explore /
  • Poster
  • / ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).

ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).

Abstract Video & Slides Poster

Authors

Mansoor Mirza

Mansoor Raza Mirza

Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet–Copenhagen University Hospital, Copenhagen, Denmark

Mansoor Raza Mirza , Robert L. Coleman , Lars Christian Hanker , Brian M. Slomovitz , Giorgio Valabrega , Ellie Im , Monica Walker , Wei Guo , Matthew A. Powell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Other Gynecologic Cancer

Clinical Trial Registration Number

NCT03981796

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS6107)

DOI

10.1200/JCO.2020.38.15_suppl.TPS6107

Abstract #

TPS6107

Poster Bd #

278

Abstract Disclosures

Similar Posters

First Author: Mansoor Raza Mirza

First Author: Ignace Vergote

First Author: Christian Marth

First Author: Nicoletta Colombo